Blood Tests May Replace Brain Scans for Tracking Alzheimer's Tau Pathology
New research identifies plasma and CSF tau biomarkers that closely mirror tau PET scans, potentially replacing costly brain imaging.
Summary
Tau PET brain scans are the gold standard for measuring tau protein buildup in Alzheimer's disease, but they are expensive and not widely available. This study from Genentech compared multiple tau protein measurements in cerebrospinal fluid and blood against tau PET results in patients ranging from early to moderate Alzheimer's. Researchers found that several CSF tau markers and two blood-based markers — phosphorylated tau at positions 181 and 217 — correlated strongly with PET imaging results. This suggests that routine blood or spinal fluid tests could one day serve as practical stand-ins for brain scans, making Alzheimer's monitoring more accessible for patients and useful in clinical trials where imaging is logistically challenging.
Detailed Summary
Measuring tau protein tangles in the brain is critical for diagnosing and tracking Alzheimer's disease progression. Tau PET imaging does this with high precision but is expensive, radiation-involving, and available only at specialized centers — limiting its use in routine care and large clinical trials. Finding blood or spinal fluid biomarkers that reliably reflect tau PET findings would be a major practical advance.
This study, led by researchers at Genentech in collaboration with C2N Diagnostics and Roche, enrolled participants with prodromal to moderate Alzheimer's disease. The team measured multiple tau species in cerebrospinal fluid (CSF; n=53) and plasma (n=181) using immunoassays and liquid chromatography-mass spectrometry, then compared these levels against [18F]GTP1 tau PET scans at baseline.
Among CSF markers, C2N-eMTBR-tau243, tau phosphorylated at threonine 205 (p-tau205), p-tau217, and an MTBR peptide (MTBR/243-254) showed the strongest correlations with tau PET standardized uptake value ratios. Importantly, plasma p-tau181 and plasma p-tau217 performed comparably to their corresponding CSF analytes in ranking against tau PET — a meaningful finding given that blood draws are far less invasive than lumbar punctures.
These results suggest that a panel of fluid tau biomarkers — especially plasma p-tau217 — could serve as accessible surrogates for tau PET in both clinical settings and drug trials. This has immediate relevance for stratifying patients and monitoring treatment response without repeated brain imaging.
Caveats include a relatively small CSF cohort and the cross-sectional design, which limits conclusions about longitudinal tracking. The summary is based on the abstract only, so full methodology, confounder adjustments, and subgroup analyses are not available for review.
Key Findings
- CSF p-tau217, p-tau205, C2N-eMTBR-tau243, and MTBR/243-254 showed the strongest correlations with tau PET imaging.
- Plasma p-tau181 and p-tau217 matched their CSF counterparts in correlation rankings against tau PET.
- Blood-based tau tests could replace invasive lumbar punctures or expensive PET scans for tau monitoring.
- Findings span prodromal to moderate Alzheimer's, suggesting utility across disease stages.
- Results may accelerate development of accessible plasma biomarker panels for Alzheimer's trials and care.
Methodology
Cross-sectional study comparing CSF (n=53) and plasma (n=181) tau species measured via immunoassay and LC-MS against [18F]GTP1 tau PET standardized uptake value ratios in prodromal to moderate Alzheimer's patients. Head-to-head analyte comparisons were performed at baseline. Full statistical methodology is not available as the summary is based on the abstract only.
Study Limitations
The CSF cohort was small (n=53), which may limit the statistical power of those comparisons. The cross-sectional design prevents conclusions about whether these biomarkers accurately track disease progression over time. This summary is based on the abstract only; full methodology, exclusion criteria, and confounder data were not available.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: